How to Evaluate a Longevity Clinic: Separating Evidence from Marketing

At a Glance

The longevity medicine industry has grown faster than its evidence base. A 2025 industry survey of 82 clinics across multiple continents found that standards of practice vary widely and that formal training in longevity medicine remains inconsistent. A parallel editorial in Aging by Marco Demaria observed that “every clinic is now marketing itself as a longevity clinic,” while pointing out that many sell biological age tests whose precision and clinical utility are still under active scientific debate (PMID 41085401). A Dubai clinic group’s survey, published in 2025, estimated that roughly 90 % of longevity clinics worldwide offer treatments shaped more by marketing than by science — a figure that is consistent with what I see when patients bring me their previous longevity workups.

The market is not all bad. A genuine subset of practitioners uses rigorous biomarker-driven protocols, titrated lifestyle programmes and carefully monitored off-label pharmacology, and that subset produces meaningful results. The challenge for a prospective patient is telling them apart. This article gives you the tools to do that.

Five Red Flags That Signal Marketing Over Medicine

1. A promised “biological age” with no explanation of which test produced it

Biological age is not a single number; it is a family of estimates derived from different data sources — epigenetic methylation clocks, phenotypic blood-marker composites, telomere length, proteomics. Each measures a different dimension of aging and has different predictive power. A 2024 systematic review of 33 clocks found that phenotypic clocks predict all-cause mortality better than chronological age, but also documented wide inter-clock disagreement in the same individual (PMID 39215995). When a clinic hands you a single number and says “you are biologically 48 instead of 56” without disclosing which clock, which tissue, and what the confidence interval is, they are selling a story, not a measurement.

2. No physician who reviews your results personally

Longevity is a medical subspecialty. Reviewing panels that include hormonal, metabolic, inflammatory, and genomic data requires a physician trained in interpreting complex biomarker interactions. A clinic staffed entirely by health coaches, nutritionists, or nurse practitioners without physician supervision falls short of this standard — however pleasant the experience.

3. Expensive supplement stacks with no preceding individualisation

Giving every patient the same longevity stack — NAD+ precursors, resveratrol, CoQ10, berberine — independent of their actual baseline markers is a supplement retail operation dressed as a clinic. These compounds have different effects in different physiological contexts. NAD+ precursors may accelerate tumour growth in patients with certain solid malignancies. Berberine is a potent CYP3A4 and P-gp inhibitor that can raise serum levels of immunosuppressants and some statins to dangerous levels. A universal stack given without testing first is a clinical shortcut, not personalised medicine.

4. No integration with your conventional care team

Genuine longevity medicine adds an interpretive layer on top of conventional risk management, not a replacement for it. A clinic that discourages you from sharing its protocol with your cardiologist, GP, or neurologist is signalling that it cannot defend its approach to peers. Evidence-based practitioners welcome that dialogue.

5. No scheduled follow-up testing

A biological age test or biomarker panel is a snapshot. It acquires clinical value only when compared to a later time point. Without a scheduled re-test at three to six months — and a clear plan for what a change in a given marker would trigger — the initial workup is a vanity product, not a monitoring programme.

What a Genuine Evidence-Informed Workup Looks Like

After more than two decades practising integrative and longevity medicine, here is the minimum I expect from a clinic that is doing this seriously.

Laboratory panel

A comprehensive metabolic panel is the foundation: fasting glucose, HbA1c, insulin, full lipid panel including apolipoprotein B and Lp(a), liver and kidney function, complete blood count, ferritin, transferrin saturation. To this I add:

• Inflammatory markers: hs-CRP, interleukin-6, homocysteine, fibrinogen
• Hormonal profile: DHEA-S, free testosterone, SHBG, oestradiol (men and women), IGF-1, TSH, fT3, fT4, reverse T3
• Nutritional markers: 25-OH vitamin D, B12 (methylmalonic acid if borderline), zinc, magnesium (intracellular preferred), omega-3 index
• Cardiovascular risk extension: LP-PLA2 or coronary artery calcium score for patients over 45
• Epigenetic age: a validated methylation clock — TruAge, GlycanAge, or the Horvath-based DunedinPACE — with explicit disclosure of the reference population and known limitations

This is not a cheap panel. But it is the kind of data that makes the difference between guessing and deciding.

Functional assessment

Cardiorespiratory fitness (VO₂max or its validated surrogate, the six-minute walk test) is one of the most powerful all-cause mortality predictors available. A UK Biobank study of 46,481 participants confirmed that higher cardiorespiratory fitness substantially offsets the mortality risk associated with accelerated biological aging — and that the worst outcomes are in people who combine accelerated aging with low fitness (PMID 40789340). Any longevity programme that does not measure fitness and prescribe a training protocol has missed the most evidence-rich lever available.

Grip strength, gait speed, and a brief cognitive battery round out the functional picture. These are low-cost, high-information tests that most expensive longevity clinics paradoxically skip in favour of proprietary technology.

Lifestyle quantification

A 2024 UK Biobank cohort study linked adherence to anti-inflammatory dietary patterns, moderate-to-high physical activity, and healthy sleep to significantly delayed biological aging and reduced all-cause mortality; the best effect on deceleration of biological aging was observed in the high physical activity group (PMID 39369207). Lifestyle adherence should be formally scored, not just discussed, so that gains and gaps can be tracked over time.

Ten Questions to Ask a Longevity Clinic Before You Pay

1. Which biological age test do you use, and can you explain its validation data?
2. Who is the supervising physician, what are their qualifications, and do they personally review my results?
3. What is included in the baseline panel, and can I see the protocol before I commit?
4. How do you individualize the protocol to my specific results rather than applying a standard stack?
5. What is your process for contraindication screening — specifically for supplements with drug interactions?
6. Will you share my protocol with my GP or specialist if I request it?
7. At what interval do you retest, and what changes in a marker would prompt a protocol change?
8. Which interventions you offer are supported by randomised controlled trial data in humans, and which are based on observational or animal data?
9. What is your approach to infections, inflammation, and immune dysregulation as drivers of accelerated aging?
10. How do you handle patients with complex histories — autoimmune disease, Lyme co-infections, post-viral syndromes?

A clinic that answers question 8 honestly — acknowledging that metformin’s longevity benefits are established in observational data but that the TAME trial’s results in healthy adults are still pending, for instance — is likely to treat the rest of your questions seriously too.

How I Think About Longevity at My Clinic

The framing I use is “find the cause before treating the symptom.” Accelerated biological aging in a 48-year-old is rarely idiopathic. It is worth asking: what is driving the inflammation driving the aging? The answer is frequently one or more of four domains.

Brain network dysregulation. Quantitative EEG and functional imaging can reveal patterns of network overactivation or disconnection that correlate with cognitive and metabolic health trajectories. When these patterns are present, targeted transcranial magnetic stimulation is the most evidence-grounded intervention I have available, and it addresses the problem rather than its biomarker.

Immune system dysregulation. hs-CRP above 1.5 mg/L without a metabolic explanation should prompt evaluation for subclinical infection, mould-related CIRS, or autoimmune activation. I find that treating the inflammatory source consistently moves epigenetic age markers more than any supplement combination.

Occult infection. Lyme disease and its co-infections (Bartonella, Babesia, Ehrlichia, reactivated HHV-6, EBV) drive chronic low-grade inflammation that shows up as accelerated aging on methylation clocks. These are systematically under-tested in conventional longevity clinics. Lyme borrelia can establish intracellular persistence and biofilm-protected forms that conventional two-week antibiotic courses do not reliably clear — a finding that changes the management equation entirely.

Relationship and social environment. The psychosocial driver of aging is the most evidence-rich and most commercially inconvenient. Chronic exposure to manipulative, abusive, or high-conflict relationships produces cortisol dysregulation, elevated IL-6, and accelerated epigenetic aging that no supplement protocol reverses while the exposure continues. A longevity workup that does not ask about the patient’s social environment is an incomplete one.

Lifestyle change — sleep hygiene, zone-2 exercise, anti-inflammatory diet, time-restricted eating — remains the highest-evidence-density intervention category available, as confirmed by the ASPREE cohort study in 11,340 older adults (PMID 37821846). I support pharmacological longevity tools (metformin, low-dose rapamycin in selected patients, targeted peptides) as adjuncts, not substitutes, for that foundation. And I am not a proponent of pure polypharmacy approaches that optimise biomarkers without addressing their underlying drivers.

Related Articles

• NAD+ IV Therapy: What to Expect at Your First Infusion
• Epigenetic Clocks Explained: TruAge, GlycanAge, OmicmAge
• Longevity Blood Panel: Which Markers Actually Matter
• Rapamycin for Longevity: What the Evidence Actually Says
• Inflammaging: Why Chronic Low-Grade Inflammation Drives Aging